Skip to main content

Table 6 Summary of phase 3 trials of ABT-450/r/ABT-267, ABT-333 plus ribavirin in hepatitis C virus genotype 1

From: Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies

Study

Population

Treatment/Duration

SVR12

PEARL-II

GT1b treatment-experienced (N = 179)

3-DAA + RBV, 12 weeks (n = 88)

97%(85/88)

  

3-DAA only, 12 weeks (n = 91)

100% (91/91)

PEARL-III

GT1b treatment-naive (N = 419)

3-DAA + RBV, 12 weeks (n = 210)

99% (209/210)

  

3-DAA only, 12 weeks (n = 209)

99% (207/209)

PEARL-IV

GT1a treatment-naive (N = 305)

3-DAA + RBV, 12 weeks (n = 100)

97% (97/100)

  

3-DAA only, 12 weeks (n = 205)

90% (185/205)

TURQUOISE-II

GT1 treatment-naive and treatment-experienced with compensated cirrhosis (N = 380)

3-DAA + RBV, 12 weeks (n = 208)

92% (191/208)

  

3-DAA + RBV, 24 weeks (n = 172)

96% (165/172)

SAPPHIRE-I

GT1 treatment-naive (N = 631)

3-DAA + RBV, 12 weeks (n = 473)

96% (455/473)

SAPPHIRE-II

GT1 treatment-experienced (N = 394)

3-DAA + RBV, 12 weeks (n = 297)

96% (286/297)

  1. SVR: Sustained virologic response. GT: Genotype. DAA: Direct acting antivirals. RBV: ribavirin.